Mimetas said today that it raised $20.5 million in a Series B round from a syndicate of investors in Asia and Europe.
The Netherlands-based company intends to use its newly-acquired funds to support global commercialization efforts for its OrganoPlate organ-on-a-chip drug-testing platform.
Get the full story at our sister site, Drug Delivery Business News.
The post Mimetas lands $21m for organ-on-a-chip tech appeared first on MassDevice.